Shots:

• The approval is based on 17 clinical trials results assessing Annovera in 2-308 women aged ≤35yrs
• The study demonstrated in prevention of 97.3% pregnancy- Pearl Index (PI) 2.98/100 women with overall satisfaction rate is 89%
• Annovera is a combination of estrogen (ethinyl estradiol- 0.15 mg/day) & Nestorone (segesterone acetate-0.013 mg/day) used for prevention of ovulation for a year (13 cycle) without any medical help

Ref: Therapeutics MD | Image: Benzinga